Date: 9 April 2020
PURECIRCLE LIMITED ("PureCircle" or "the Company" or "the Group")
Unaudited Interim Results and Trading Update
PureCircle (LSE: PURE), the world's leading producer and innovator of great-tasting stevia sweeteners for the global beverage and food industry, today announces its unaudited interim results for the six-months ended 31 December 2019 ("1H FY20"), together with a trading update for the 2 months period to 29 February 2020.
Unaudited Interim Results
The unaudited interim results 1H FY20 have been prepared using revenue cut-off procedures and costing methodology that are consistent with the Company's full year 2019 audited financial results published recently.
The comparative prior period's 1H FY19 results have been restated to reflect the adjustments made in the Company's full year 2019 audited financial results.
INTERIM RESULTS HIGHLIGHTS
- Sales declined 6.0% to
- 1H FY20 sales of our new proprietary stevia leaf sweetener, PCS-3028, which increases stevia solubility by 10x compared to earlier generation stevia sweeteners, has resulted in the shift from Basic Ingredients to Breakthrough products.
- Gross margin during the period was 22.9% (1H FY19: 26.6% - this comparative excludes the
- Adjusted EBITDA during the period was negative
- Net loss for H1 FY20 of
- Operating cash flow before working capital changes of negative
- Net debt of
SUMMARY OF FINANCIALS
Period ended 31 December (USD'm) |
1H FY20 |
1H FY19 |
|
|
|
(Restated*) |
|
|
|
|
|
Sales |
46.8 |
49.7 |
|
Gross profit / (loss) |
10.7 |
(11.0) |
|
Gross margin |
22.9% |
(22.1)% |
|
Operating loss* |
(8.8) |
(21.9) |
|
Adjusted EBITDA* |
(3.1) |
(22.3) |
|
Net loss for the financial period |
(13.8) |
(28.8) |
|
Loss Per Share (fully diluted) (US Cents) |
(7.48) |
(16.52) |
|
Net assets |
146.1 |
177.3 |
|
Operating cash flow before working capital changes |
(1.8) |
3.8 |
|
Net cash (used in) / generated from operating activities |
(12.0) |
2.9 |
|
Net debt* |
(82.6) |
(103.5) |
|
* Operating loss, adjusted EBITDA and net debt are non-GAAP alternative performance measures and are laid out in Note 8.
The 1H FY20 results comprising the statement of comprehensive income; cash flow statements; statement of financial position; and statement of equity; together with prior period comparatives are also set out on Appendix 1.
Sales: Sales of
During the period, the Company exited a long standing but limiting exclusivity contract. The Company can now regain its unique ability to offer these widely used ingredients, NSF 02 flavour solution and Glycosylated Steviol Glycosides (GSG) sweetener, directly to its customers.
Solid growth continues to be achieved in
Gross margin: Higher production costs incurred due to change in production mix on certain products led to a gross margin of 22.9% (1H FY19: 26.6% - this comparative excludes the
Adjusted EBITDA: Current period adjusted EBITDA was negative
Net loss for the period: The 1H FY20 net loss of
Loss per Share (LPS): The Group recorded a 1H FY20 loss per share of
Operating cash flow before working capital: The Group recorded an outflow of
Net debt: Net debt of
Commenting on the 1H FY20 interim results, the Group CEO Peter Lai said:
"In the 1H FY20, the underlying business fundamentals remain stable even though the sales for the 6-month period decreased by 6% over the same period the year prior. PureCircle continues to be the global leader in stevia ingredient innovation and production. The Company has continued to execute its four key growth strategies - implementing a customer-centric structure and culture, diversifying the customer base, shifting the product mix to next generation ingredients, and expanding sales into additional priority consumer product categories. These efforts have shown meaningful results.
"The stevia ingredients business has become more competitive in recent years. That has impacted both the pricing for Reb A and the Company's margins. PureCircle anticipated this trend and in order to safeguard the business from this price erosion, the Company began aggressively shifting the product portfolio, including flavour solutions and blends, to taste-advantaged, exclusive ingredients based on Reb M. In addition, the Company exclusively developed a new stevia variety making this product more scalable, efficient and cost effective for customers. These advances continue to be protected by the Company's expansive patent portfolio and intellectual property library.
"In executing its existing plans, the Group anticipates headwinds from the slowdown in the global economy as a result of COVID-19. Our refinery in
"Recognising that our profitability has come under pressure partly due to its high overheads, fixed cost base and G&A expenses, the Group will carry out a series of measures over the next 12 months to improve cost efficiency in all its functions across the Group. In meeting its liquidity needs as well as improving the health of the Group's balance sheet, the Company intends to refinance its banking facilities through various options including equity infusion."
BUSINESS DEVELOPMENTS
In the last six months, the Group made a number of strategic decisions to strengthen PureCircle and its prospects for long-term growth. The Group restructured its senior management and Board of Directors to strengthen its corporate governance and financial oversight.
PureCircle enhanced future business prospects by exiting a long standing but limiting exclusivity contract. The Company can now regain its unique ability to offer these widely used ingredients, NSF 02 flavour solution and Glycosylated Steviol Glycosides (GSG) sweetener, directly to its customers.
PureCircle holds comprehensive patent and intellectual property protection over NSF 02 which is a proprietary product.
Market Opportunities
The global stevia market continues to grow. PureCircle is positioning itself to deliver the best-tasting, zero-calorie, natural sweeteners and flavours to food and beverage companies to meet consumers' demands.
PureCircle has expanded and strengthened its Commercial team to enhance our ability to fully capture the market opportunity, focused on setting and implementing a set of key strategies aimed at delivering the next chapter of growth for PureCircle.
These new strategies involve transforming the business to scale, produce and sell breakthrough superior-tasting, natural stevia ingredients and commercialise new technologies. Our commitment to next generation ingredients and improving taste and consumer experience has, as expected, led to slower immediate short term sales growth. Our focus is on product development, which has a long sell cycle, and we believe this is an important long-term investment, both in consumers' adoption of stevia and longer term sales. Customers are now switching and reformulating to next generation stevia leaf ingredients due to the superior taste profile, improved sweetness quality and enhanced mouthfeel experience.
The reformulations using our new generation stevia ingredients have led to some cannibalisation of the base business and the results should be read in this context. We are getting positive feedback about the great taste of our next generation stevia leaf sweeteners and flavours in customers' products.
Market conditions continue to be favourable for usage of stevia to expand, as beverage and food companies seeks to lower sugar and calorie levels with a natural sweetener and flavor modifiers. PureCircle will continue to capitalize on that with its range of plant-based stevia leaf solutions. In addition, globally, the regulatory climate for use of our stevia sweeteners continues to improve.
In addition to sweeteners and flavours, we provide our customers with tailored and category specific blends of our robust portfolio of stevia leaf ingredients. Our industry-leading formulation expertise allows us to maximize taste with the most cost-efficient use of stevia ingredients. With our next generation stevia solutions, we work in partnership with our customers to achieve the taste profile they require for their products in their different markets around the globe.
Strategy evolution as a result of innovation
We are exploring new areas including using our stevia flavours for sodium reduction and masking undesirable flavour characteristics of other ingredients in various food and beverage categories. This will provide consumers a great-tasting, plant-based ingredient.
We are also planning to expand our offerings of stevia leaf ingredients to include, not just sweeteners and flavours, but also protein, fibre and antioxidant ingredients - all from the stevia plant.
This will enable PureCircle to utilize much more of each stevia leaf. As such, the Company will be able to make each leaf "work harder".
The technologies to produce the products PureCircle sells are covered by patents, applied for patents and other intellectual property rights. PureCircle's broad and strong global array of patents are the result of its advanced innovation, research and development work with stevia and its investment therein. To date, PureCircle has been granted more than 200 stevia-related patents, with more than 300 patents pending covering a wide range of stevia related products and processes.
PureCircle's patent coverage and other intellectual property reflect its expertise and innovation with stevia. That expertise and innovation enables PureCircle to provide unparalleled support to its customers as they develop zero- and low-sugar food and beverage products and other products using stevia.
Management and Board Changes
The Board comprises a Non-Executive Chairman (who was independent on appointment), two Executive Directors; a Senior Independent Director; three Independent Non-Executive Directors and a Non-Independent Non-Executive Director.
Changes to the Board during the 6-months period to 31 December 2019 and up to the publication of the 1H FY20 financial results have already been included in our public disclosures.
Trading Update to February 2020
Revenue Update
Revenue in January and February 2020 totalled
While customers continue to place new sales orders, management foresee that revenue will be depressed across all regions as a result of the COVID-19 outbreak.
Balance Sheet and Liquidity
Net debt as at 29 February 2019 was $93.4 million.
There could be further drawdown on the revolving credit facility, subject to the prior approval of the bank syndicate and the Group is expected to continue to service loan amortisation as scheduled.
The Company intends to refinance its banking facilities to ensure the Group can meet its liquidity needs. The Group will endeavour to conserve its cash flow by proactively managing its capital expenditure and working capital as well as implementing cost efficiency measures that will not impact the long-term viability of the Group.
Outlook
We expect the business to generate positive cash flows, however, we may face difficulty in sustaining profit margins in the short term. There is also a risk, particularly in relation to COVID-19, that the Group may not have sufficient liquidity up until the bank facility is required to be repaid in November 2020.
Our refinery in
Whilst our supply chain remains robust, we are taking steps to mitigate our risks. We are actively monitoring and managing our inventory level and liquidity positions in this unprecedented uncertain period. In addition, the Group will be identifying opportunities for cost savings to a more appropriate cost base to ensure it remains competitive in the market that it operates in.
Given the level of uncertainty in our markets and economic uncertainties arising from the COVID-19 pandemic, the outlook for the full year is now more cautious than before.
Enquiries:
Investors/Analysts
Jimmy Lim, CFO
Email: Jimmy.Lim@purecircle.com
Phone: +6012 326 2908
Newgate Communications, Media Relations
Elisabeth Cowell
Giles Croot
Email: purecircle@newgatecomms.com
Phone: +44 (0) 20 3757 6880
Webcast and Conference Call Details
There will be no analyst presentation for the unaudited H1 FY20 financial results.
Notes to Editors
About PureCircle
· PureCircle is the only company that combines advanced R&D with full vertical integration from farm to high-quality, great-tasting innovative stevia sweeteners.
· The Company collaborates with farmers who grow the stevia plants and with food and beverage companies which seek to improve their low- and no-calorie formulations using a sweetener from plants.
· PureCircle will continue to: lead in research, development and innovation; produce a growing supply of multiple varieties of stevia sweeteners with sugar-like taste, using all necessary and appropriate methods of production; and be a resource and innovation partner for food and beverage companies.
· PureCircle stevia flavor modifiers work in synergy with sweeteners to improve the taste, mouthfeel and calorie profile, and enhance the cost effectiveness, of beverage and food products.
· Founded in 2002, PureCircle is continually investing in breakthrough research and development and it has been granted over 214 stevia-related patents with more than 300 applied for patents pending.
· PureCircle has offices around the world with the global headquarters in
· To meet growing demand for stevia sweeteners, PureCircle is rapidly ramping up its supply capability. It completed expansion of its Malaysian stevia extract facility in March 2017, increasing its capacity to rapidly supply the newer and great-tasting specialty stevia sweeteners and helping provide ever-increasing value to its customers.
· PureCircle's shares are listed on the main market of the London Stock Exchange.
· For more information, visit: www.purecircle.com
About stevia
· Given the growing global concerns about obesity and diabetes, beverage and food companies are working responsibly to reduce sugar and calories in their products, responding to both consumers and health and wellness advocates. Sweeteners from the stevia plant offer sugar-like taste and are becoming an increasingly important tool for these companies.
· Like sugar, stevia sweeteners are from plants. But unlike sugar, they enable low-calorie and zero-calorie formulations of beverages and foods.
· Stevia leaf extract is a natural-based, zero calorie, high-intensity sweetener, used by global food and beverage companies as a great-tasting zero-calorie alternative to sugar and artificial sweeteners.
· Stevia is a naturally sweet plant native to
· The sweet-tasting parts of the stevia leaf are up to 350 times sweeter than sugar: stevia's high-intensity sweetness means it requires far less water and land than sugar.
· Research has shown that the molecules of the stevia leaf are present and unchanged in the dried stevia leaf, through the commercial extraction and purification process, and in the final stevia leaf extract product. All major global regulatory organisations, across 65 countries, have approved the use of high-purity stevia leaf extracts in food and beverages.
· For more information on the science of stevia, please visit https://www.purecirclesteviainstitute.com/
APPENDIX 1
Condensed consolidated statement of comprehensive income
for the period ended 31 December 2019
|
Notes |
|
Unaudited Six months ended |
||
|
|
|
31 December |
|
31 December |
|
|
|
2019 |
|
2018 |
|
|
|
|
|
(Restated*) |
|
|
|
USD'000 |
|
USD'000 |
Continuing operations |
|
|
|
|
|
Revenue |
|
|
46,810 |
|
49,675 |
Cost of sales |
|
|
(36,074) |
|
(60,650) |
Gross profit / (loss) |
|
|
10,736 |
|
(10,975) |
|
|
|
|
|
|
Other income |
4 |
|
154 |
|
5,800 |
Other expenses |
5 |
|
(410) |
|
(5,310) |
Administrative expenses |
|
|
(19,713) |
|
(16,916) |
Finance income |
|
|
56 |
|
153 |
Finance costs |
|
|
(4,137) |
|
(4,740) |
Share of gain/(loss) in joint venture |
|
|
4 |
|
(78) |
Loss before taxation |
|
|
(13,310) |
|
(32,066) |
Income tax (expense) / credit |
13 |
|
(485) |
|
3,247 |
Loss for the period |
|
|
(13,795) |
|
(28,819) |
|
|
|
|
|
|
Other comprehensive income / (loss) (net of tax): |
|
|
|
|
|
Items that may be reclassified subsequently to (loss)/profit: |
|
|
|
|
|
Exchange difference arising on translation of foreign operations |
|
|
136 |
|
(5,517) |
Fair value loss on derivative financial instruments1 |
|
|
- |
|
(469) |
|
|
|
136 |
|
(5,986) |
Total comprehensive loss for the period (net of tax) |
|
|
(13,659) |
|
(34,805) |
|
|
|
|
|
|
Loss for the financial period attributable to: |
|
|
|
|
|
Owners of the Company |
|
|
(13,795) |
|
(28,819) |
|
|
|
(13,795) |
|
(28,819) |
|
|
|
|
|
|
Total comprehensive loss attributable to: |
|
|
|
|
|
Owners of the Company |
|
|
(13,659) |
|
(34,805) |
|
|
|
(13,659) |
|
(34,805) |
|
|
|
|
|
|
Loss per share (US cents) |
|
|
|
|
|
Basic |
15 |
|
(7.48) |
|
(16.52) |
Diluted |
15 |
|
(7.48) |
|
(16.52) |
*Refer to Note 20.
1 Changes in the fair value of derivative instruments at fair value through other comprehensive income.
Condensed consolidated statement of financial position
as at 31 December 2019
|
|
|
Unaudited |
Audited |
|
|
|
31 December |
30 June |
|
Notes |
|
2019 |
2019 |
|
|
|
USD'000 |
USD'000 |
|
|
|
|
|
Assets |
|
|
|
|
Non-current assets |
|
|
|
|
Property, plant and equipment |
9 |
|
93,305 |
95,294 |
Intangible assets |
9 |
|
48,074 |
47,564 |
Prepaid land lease payments |
|
|
1,700 |
1,794 |
Deferred tax assets |
|
|
2,570 |
2,221 |
Right-of-use |
9 |
|
4,880 |
- |
|
|
|
150,529 |
146,873 |
|
|
|
|
|
Current assets |
|
|
|
|
Inventories |
10 |
|
100,373 |
89,242 |
Trade receivables |
|
|
23,009 |
40,266 |
Other receivables and prepayments |
|
|
6,790 |
6,893 |
Tax recoverable |
|
|
1,408 |
1,512 |
Restricted cash |
|
|
51 |
215 |
Cash and bank balances |
|
|
5,102 |
25,460 |
Financial assets at fair value through profit or loss |
|
|
- |
1,748 |
|
|
|
136,733 |
165,336 |
Total assets |
|
|
287,262 |
312,209 |
|
|
|
|
|
Equity and liabilities |
|
|
|
|
Equity |
|
|
|
|
Share capital |
14 |
|
18,445 |
18,436 |
Share premium |
14 |
|
260,265 |
259,999 |
Foreign exchange translation reserve |
|
|
(19,999) |
(20,135) |
Share option reserve |
|
|
2,061 |
2,099 |
Accumulated losses |
|
|
(114,717) |
(100,922) |
Equity attributable to owners of the Company |
|
|
146,055 |
159,477 |
Total equity |
|
|
146,055 |
159,477 |
|
|
|
|
|
Non-current liabilities |
|
|
|
|
Deferred tax liabilities |
|
|
668 |
3 |
Other payables and accruals |
11 |
|
346 |
403 |
Lease liabilities |
|
|
4,067 |
- |
Derivative financial instruments |
12 |
|
1,157 |
1,446 |
|
|
|
6,238 |
1,852 |
|
|
|
|
|
Current liabilities |
|
|
|
|
Trade payables |
11 |
|
27,047 |
33,190 |
Other payables and accruals |
|
|
19,106 |
23,285 |
Lease liabilities |
|
|
931 |
- |
Income tax liabilities |
|
|
132 |
134 |
Short-term borrowings |
11 |
|
87,753 |
94,271 |
|
|
|
134,969 |
150,880 |
Total liabilities |
|
|
141,207 |
152,732 |
Total equity and liabilities |
|
|
287,262 |
312,209 |
|
|
|
|
|
Condensed consolidated statement of changes in equity
for the period ended 31 December 2019
|
|
|
Attributable to owners of the Company |
|
||||
|
|
|
|
Foreign |
Share |
|
|
|
|
|
|
|
exchange |
based |
|
|
|
|
|
Share |
Share |
translation |
payment |
Derivative |
Accumulated |
Total |
|
|
capital |
premium |
reserve |
reserve |
reserve |
losses |
equity |
|
|
USD'000 |
USD'000 |
USD'000 |
USD'000 |
USD'000 |
USD'000 |
USD'000 |
|
|
|
|
|
|
|
|
|
Balance at 1 July 2019 |
|
18,436 |
259,999 |
(20,135) |
2,099 |
- |
(100,922) |
159,477 |
|
|
|
|
|
|
|
|
|
Loss for the period |
|
- |
- |
- |
- |
- |
(13,795) |
(13,795) |
Other comprehensive income |
|
- |
- |
136 |
- |
- |
- |
136 |
Total comprehensive income/(loss) for the period (net of tax) |
|
- |
- |
136 |
- |
- |
(13,795) |
(13,659) |
|
|
|
|
|
|
|
|
|
Share award compensation expense granted during the period |
|
- |
- |
- |
- |
- |
- |
- |
Exercise of share options |
|
9 |
266 |
- |
(38) |
- |
- |
237 |
Balance at 31 December 2019 |
|
18,445 |
260,265 |
(19,999) |
2,061 |
- |
(114,717) |
146,055 |
|
|
|
Attributable to owners of the Company |
|
||||
|
|
|
|
Foreign |
Share |
|
|
|
|
|
|
|
exchange |
based |
|
|
|
|
|
Share |
Share |
translation |
payment |
Derivative |
Accumulated |
Total |
|
|
capital |
premium |
reserve |
reserve |
reserve |
losses |
equity |
|
|
USD'000 |
USD'000 |
USD'000 |
USD'000 |
USD'000 |
USD'000 |
USD'000 |
|
|
|
|
|
|
|
|
|
Balance at 1 July 2018 |
|
17,428 |
225,504 |
(14,155) |
2,167 |
- |
(4,498) |
226,446 |
Impact of correction, net of tax |
|
- |
- |
149 |
- |
- |
(16,428) |
(16,279) |
Balance at 1 July 2018 (Restated*) |
|
17,428 |
225,504 |
(14,006) |
2,167 |
- |
(20,926) |
210,167 |
Adjustment on adoption of IFRS 9 |
|
- |
- |
- |
- |
- |
(323) |
(323) |
Balance at 1 July 2018 (Restated*) |
|
17,428 |
225,504 |
(14,006) |
2,167 |
- |
(21,249) |
209,844 |
|
|
|
|
|
|
|
|
|
Loss for the period |
|
- |
- |
- |
- |
- |
(28,819) |
(28,819) |
Other comprehensive loss |
|
- |
- |
(5,517) |
- |
(469) |
- |
(5,986) |
Total comprehensive loss for the period (net of tax) |
|
- |
- |
(5,517) |
- |
(469) |
(28,819) |
(34,805) |
|
|
|
|
|
|
|
|
|
Share award compensation expense granted during the period |
|
- |
- |
- |
- |
- |
- |
- |
Exercise of share options |
|
56 |
2,219 |
- |
(29) |
- |
- |
2,246 |
Balance at 31 December 2018 (Restated*) |
|
17,484 |
227,723 |
(19,523) |
2,138 |
(469) |
(50,068) |
177,285 |
*Refer to Note 20.
Condensed consolidated cash flow statement
for the period ended 31 December 2019
|
|
Unaudited Six months ended |
||
|
|
31 December |
31 December |
|
|
|
2019 |
2018 |
|
|
|
|
(Restated*) |
|
|
|
USD'000 |
USD'000 |
|
CASH FLOWS FROM OPERATING ACTIVITIES |
|
|
|
|
Loss before taxation |
|
(13,310) |
(32,066) |
|
|
|
|
|
|
Adjustments for:- |
|
|
|
|
|
|
|
|
|
Amortisation of deferred income |
|
(78) |
(36) |
|
Amortisation of intangible assets |
|
1,092 |
957 |
|
Amortisation of prepaid land lease payments |
|
69 |
77 |
|
Depreciation of property, plant and equipment |
|
3,894 |
3,991 |
|
Depreciation on right-of-use |
|
574 |
- |
|
Amortisation of borrowing transaction cost |
|
1,075 |
951 |
|
Interest expense |
|
3,172 |
3,790 |
|
Interest income |
|
(57) |
(153) |
|
Finance lease on right-of-use |
|
179 |
- |
|
Fair value gain on interest rate swaps |
|
(289) |
- |
|
Loss/(Gain) on disposal of property, plant and equipment |
|
41 |
(118) |
|
Share based payments |
|
237 |
2,246 |
|
Inventories written back |
|
1 |
38 |
|
Write down of inventories to net realisable value |
|
- |
24,170 |
|
Intangible assets written off |
|
- |
2,500 |
|
Unrealised foreign exchange loss |
|
1,985 |
2,877 |
|
Share of (gain)/loss in joint venture |
|
(4) |
78 |
|
Bad debts written off |
|
11 |
- |
|
Write back of expected credit loss on trade receivables |
|
(560) |
- |
|
Expected credit loss on other receivables |
|
155 |
- |
|
Compensation of termination on R&D project |
|
- |
(5,500) |
|
Operating cash flow before working capital changes |
|
(1,813) |
3,802 |
|
|
|
|
|
|
Increase in inventories |
|
(11,133) |
(8,495) |
|
Decrease in trade and other receivables |
|
17,201 |
19,007 |
|
Decrease in trade and other payables |
|
(13,038) |
(6,807) |
|
NET CASH (USED IN) / GENERATED FROM OPERATIONS |
|
(8,783) |
7,507 |
|
|
|
|
|
|
Interest received |
|
57 |
153 |
|
Interest paid |
|
(2,940) |
(3,733) |
|
Tax paid |
|
(539) |
(1,021) |
|
Tax refund |
|
289 |
- |
|
Transaction cost paid for loan acquisition |
|
(93) |
(55) |
|
NET CASH (USED IN) / GENERATED FROM OPERATING ACTIVITIES |
|
(12,009) |
2,851 |
|
|
|
|
|
|
Condensed consolidated cash flow statement
for the period ended 31 December 2019 (continued)
|
|
Unaudited Six months ended |
||
|
|
31 December |
31 December |
|
|
|
2019 |
2018 |
|
|
|
|
(Restated*) |
|
|
|
USD'000 |
USD'000 |
|
|
|
|
|
|
BALANCE BROUGHT FORWARD |
|
(12,009) |
2,851 |
|
|
|
|
|
|
CASH FLOWS FOR INVESTING ACTIVITIES |
|
|
|
|
Addition of intangible assets |
|
(1,648) |
(4,019) |
|
Purchase of property, plant and equipment |
|
(1,436) |
(2,530) |
|
Proceeds from disposal of property, plant and equipment |
|
23 |
571 |
|
Increase in investment in a joint venture |
|
- |
(205) |
|
Proceeds from sales of financial assets at fair value through profit or loss |
|
1,748 |
- |
|
Proceeds from liquidation of a joint venture |
|
123 |
- |
|
|
|
|
|
|
NET CASH USED IN INVESTING ACTIVITIES |
|
(1,190) |
(6,183) |
|
|
|
|
|
|
CASH FLOWS FOR FINANCING ACTIVITIES |
|
|
|
|
Repayment of borrowings |
|
(7,500) |
(5,000) |
|
Increase in restricted cash |
|
163 |
1 |
|
|
|
|
|
|
NET CASH USED IN FINANCING ACTIVITIES |
|
(7,337) |
(4,999) |
|
|
|
|
|
|
NET DECREASE IN CASH AND CASH EQUIVALENTS |
|
(20,536) |
(8,331) |
|
|
|
|
|
|
Effects of foreign exchange rate changes on |
|
178 |
(1,003) |
|
cash and cash equivalents |
|
|
|
|
|
|
|
|
|
CASH AND CASH EQUIVALENTS |
|
|
|
|
AT BEGINNING OF THE FINANCIAL PERIOD |
|
25,460 |
23,935 |
|
CASH AND CASH EQUIVALENTS AT END OF THE |
|
|
|
|
FINANCIAL PERIOD |
|
5,102 |
14,601 |
|
|
|
|
|
|
*Refer to Note 20.
The cash and bank balances of
The net cash outflow for the purchases of property, plant and equipment during the financial is as follows:
|
|
31 December |
|
31 December |
|
|
2019 |
|
2018 |
|
|
USD'000 |
|
USD'000 |
Additions for the financial period |
|
1,961 |
|
2,865 |
Payment made for previous year additions |
|
371 |
|
420 |
Amount not yet due for payment |
|
(896) |
|
(755) |
Total cash payments during the financial period |
|
1,436 |
|
2,530 |
Reconciliation of bank borrowings arising from financing activities:
|
|
31 December |
|
31 December |
|
|
2019 |
|
2018 |
|
|
USD'000 |
|
USD'000 |
As at 1 July |
|
94,271 |
|
122,092 |
Cash impact: |
|
|
|
|
Principal and interest payment |
|
(7,500) |
|
(5,000) |
Transaction cost |
|
(93) |
|
(55) |
Non-cash impact: |
|
|
|
|
Amortisation |
|
1,075 |
|
951 |
Foreign exchange movement |
|
- |
|
171 |
As at 31 December |
|
87,753 |
|
118,159 |
*Refer to Note 20. |
|
|
|
|
Notes to interim financial statements
1. General information
The Company was incorporated and registered as a private limited company in
The Company is engaged principally in the business of investment holding whilst the principal activities of the rest of the Group are the production, marketing and distribution of speciality natural ingredients based upon high purity stevia.
The unaudited condensed consolidated interim financial statements have been authorised for issue by the Board of Directors on 8 April 2020.
The prior period financial position and comprehensive income have been restated to correct errors with respect of revenue, inventory and cost of goods sold. Although there was no impact to our actual cash generation, the Group has restated the statement of cash flows to reflect the impact of these changes on profit and other relevant financial statement line items. Please refer to Note 20 for additional details.
2. Basis of preparation
The condensed consolidated financial information comprises the unaudited interim financial information for the six months to 31 December 2019 and 31 December 2018. The condensed consolidated interim financial statements has been prepared on a going concern basis in accordance with IAS 34, "Interim Financial reporting" as issued by International Accounting Standards Board ("IASB") and the Disclosure and Transparency Rules issued by the Financial Conduct Authority.
The condensed consolidated interim financial statement does not include all the notes of the type normally included in an annual financial report. Accordingly, the condensed consolidated interim financial statements should be read in conjunction with the annual report for the year ended 30 June 2019 and any public announcements made by PureCircle Limited during the interim reporting period.
Changes in accounting policy and disclosures
This condensed consolidated information has been prepared under the historical cost convention and on a basis consistent with the IFRS accounting policies as set out in the Annual Report for the year ended 30 June 2019, except that the Group has adopted the following new standard that are first effective for the current accounting period of the Group:
a) IFRS 16, "Leases" (effective from 1 July 2019) supersedes IAS 17 "Leases" and the related interpretations. IFRS 16 eliminates the classification of leases by the lessee as either finance leases or operating leases. IFRS 16 introduces a single accounting model, requiring the lessee to recognise the "right-of-use" of the underlying asset and the lease liability reflecting future lease payment liabilities in the statement of financial position. The right-of-use asset is depreciated in accordance with the principles in IFRS 116 "Property, Plant and Equipment" and the lease liability is accreted over time with interest expense recognised in the statement of comprehensive income.
The Group will adopt IFRS 16 retrospectively from 1 July 2019, via the simplified transition approach and will therefore not restate the comparatives for the 2018 reporting period, as permitted under the specific transitional provisions in the standard. The reclassifications and the adjustments arising from the new leasing rules will therefore be recognised in the opening consolidated statement of financial position on 1 July 2019.
Key judgements and estimates made in calculating the initial impact of adoption include assessing whether arrangements contain a lease, determining the lease term, and calculating the discount rate. The lessee's incremental borrowing rate applied to the lease liabilities on 1 July 2019 will be a range of 4.0% to 12.1%.
On adoption of IFRS 16, the Group will recognise lease liabilities in relation to leases which had previously been classified as "operating leases" under the principles of IAS 17. These liabilities are measured at the present value of the remaining lease payments.
On a lease-by-lease basis, the Group measures the associated right-of-use asset on a retrospective basis either at its carrying amount as if the new rules had always been applied or at the amount equal to the lease liability, adjusted by the amount of any prepaid or accrued lease payments relating to that lease recognised in the statement of financial position as at 30 June 2019.
In applying IFRS 16 for the first time, the Group will apply the following practical expedients:
- The use of a single discount rate to a portfolio of leases with reasonably similar characteristics;
- Reliance on previous assessments on whether leases are onerous;
- The accounting for operating leases with remaining lease terms of less than 12 months as short term leases as at the date of initial application;
- The exclusion of initial direct costs for the measurement of the right-of-use assets at the date of initial application; and
- The use of hindsight in determining the lease terms where the contracts contain options to extend or terminate the leases. The Group has also elected not to reassess whether a contract is, or contains a lease at the date of initial application. Instead, for contracts entered into before the transition date, the Group relied on its assessment made by applying IFRS 117 and IFRIC 4 "Determining whether an Arrangement contains a Lease".
The Group will recognise new assets and liabilities for its operating leases of warehouses, offices, apartments, gas tanks, laptops, and photocopiers. The Group recognise lease liabilities equal to the right-of-use assets of
|
|
USD'000 |
Operating lease commitments disclosed as at 30 June 2019 |
|
5,534 |
Less: Discounted using the lessee's incremental borrowing rate of at the |
|
|
date of initial application |
|
(1,429) |
Less: Short-term leases recognised on a straight-line basis as expense |
|
(43) |
Add: Adjustments as a result of a different treatment of extension |
|
|
options |
|
1,346 |
Lease liabilities recognised as at 1 July 2019 |
|
5,408 |
|
|
|
In light of the impairment recorded during the year, the Group has considered the recoverable amount of the CGU that retains the right of use ("ROU") assets and has concluded that there is no impairment required on the ROU assets. |
||
|
|
|
Of which are: |
|
|
Current lease liabilities |
|
1,325 |
Non-current lease liabilities |
|
4,083 |
Lease liabilities recognised as at 1 July 2019 |
|
5,408 |
Upon the adoption of IFRS 16, there will be an immaterial benefit to operating profit and a corresponding increase in finance expense from the presentation of a portion of lease costs as interest costs. Profit before tax and earnings per share are not expected to be significantly impacted. The adoption of IFRS 16 will have no impact on the Group's cash flows except to present cash outflows as financing, instead of operating.
There are no other standards that are not yet effective and that would be expected to have a material impact on the entity in the current or future reporting periods and on foreseeable future transactions.
3. Exceptional items
|
Six months to |
Six months to |
|
31 December 2019 |
31 December 2018 |
|
|
(Restated*) |
|
(US |